Lee S. Schwartzberg MD, FACP
Chief, Medical Oncology and Hematology, Renown Institute for Cancer, and Professor of Clinical Medicine, University of Nevada, Reno, NevadaDr. Lee Schwartzberg is Chief, Medical Oncology and Hematology at the Renown Institute for Cancer and Professor of Clinical Medicine at the University of Nevada, Reno. He completed his hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center and spent 3 decades at West Cancer Center and Research Institute as Medical Director. He was Chief, Division of Hematology/Oncology and Professor of Medicine at the University of Tennessee Health Science Center from 2012 to 2017.
In 2018, he became the founding Chief Medical Officer of OneOncology, a national oncology practice management company and served in that role through 2021. He previously served on the Board of Directors and the Guideline Steering Committee of the National Comprehensive Cancer Network and participated in several guideline committees, including the committee for breast cancer.
Dr. Schwartzberg has published nearly 300 peer-reviewed manuscripts, book chapters, and monographs. He is the founding Editor-in-Chief of the Elsevier website PracticeUpdate Oncology and the founding Editor-in-Chief of the journal Community Oncology. His research interests focus on breast cancer, supportive care, precision medicine, and patient-reported outcomes. Dr. Schwartzberg maintains a clinical practice in breast cancer.
Disclosures
- Consultant: Amgen; Pfizer; Helsinn; Genentech; BMS (Bristol; Myer; Squibb); Myriad; AstraZeneca; Spectrum; Napo
- Advisory boards: Genomic Health Research Funding (Institution): Amgen; DSMB: Bayer
Recent Contributions to PracticeUpdate:
- CLEOPATRA Trial Changes Standard Therapy for Metastatic HER2 Positive Breast Cancer
- Addition of Aprepitant Reduced Chemotherapy-Induced Nausea and Vomiting
- Dr. Lee Schwartzberg’s ESMO 2014 Recommendations in Biomarkers
- Dr. Lee Schwartzberg’s ESMO 2014 Recommendations in Breast Cancer
- Addition of Everolimus Did Not Prolong Overall Survival in HR+ HER2-Negative Advanced Breast Cancer
- PIK3CA Mutations Associated With Lower Response in HER2-Positive Breast Cancer
- Long-Term Follow-Up of Breast Cancer Patients With Negative Node and No Axillary Dissection
- Lapatinib With Trastuzumab for HER2-Positive Early Breast Cancer
- PI3K/AKT Mutations Do Not Seem to Impact Residual Risk After Endocrine Therapy
- PALB2 Mutations Increase Breast Cancer Risk